Apatinib is a new small molecule selective vascular endothelial growth factor receptor 2 (VEGFR-2) tyrosine kinase inhibitor, and is effective for advanced gastric adenocarcinoma, non-small cell lung cancer (NSCLC), breast cancer, gynecological cancer, hepatocellular carcinoma (HCC), thyroid cancer and sarcoma. This evidence concerns the gene KDR and non-small cell lung carcinoma.